Windlas Biotech Ltd IPO

Last Updated: 14 December 2021 8:07 PM by 5Paisa

Windlas Biotech IPO Synopsis

Windlas Biotech Ltd., one of the top companies in pharmaceutical formulations contract development and manufacturing organizations (CDMO) in India is launching its Initial Public Offer on August 4th. Windlas will raise Rs.402 crore through a mix of fresh issue and offer for sale. The IPO will close for subscription on 06 August. The price band for the IPO is fixed in the range of Rs.448-460. 

Windlass Biotech Shareholding Pattern

Object of the offer:

The company proposes to utilise the net proceeds from the issue for 
1. Purchase of equipment required for capacity expansion of existing facility at Dehradun Plant
2. To meet working capital requirements
3. Repaying of certain borrowings

Windlas Biotech Limited is amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India in terms of revenue (Source: CRISIL Report). The company manufactures both solid and liquid pharmaceutical dosage forms and has significant experience in providing specialized capabilities, including high potency, controlled substances and low-solubility. Windlas Biotech provide a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics.

Windlass Biotech - Financials